The third case in a three-part series, this article chronicles the treatment journey of a 50-year-old male patient who had been diagnosed with left-sided colon cancer in January 2016. After multiple FOLFOX doses, FOLFIRI cycles, and resection, the patient began treatment with regorafenib in July 2020 as a third-line treatment, with the hope that this […]
According to research presented at the virtual ASCO GI Cancers Symposium from the phase 3 ALTER0703 trial, anlotinib was beneficial in Chinese patients with refractory metastatic colorectal cancer (CRC), with particular overall survival (OS) improvement – the primary endpoint – among patients with RAS/KRAS/BRAF-wildtype.
In this Original Investigation from JAMA Oncology, the authors attempt to discover whether increased coffee consumption is associated with improved survival in patients with advanced or metastatic colorectal cancer. Overall survival (OS) and progression-free survival (PFS) were the main outcomes and measures, and both decaffeinated and caffeinated coffee were studied.